NO20014893L - Farmasoytiske sammensetninger av erythropoietin - Google Patents

Farmasoytiske sammensetninger av erythropoietin

Info

Publication number
NO20014893L
NO20014893L NO20014893A NO20014893A NO20014893L NO 20014893 L NO20014893 L NO 20014893L NO 20014893 A NO20014893 A NO 20014893A NO 20014893 A NO20014893 A NO 20014893A NO 20014893 L NO20014893 L NO 20014893L
Authority
NO
Norway
Prior art keywords
erythropoietin
pharmaceutical compositions
pharmaceutical
compositions
Prior art date
Application number
NO20014893A
Other languages
English (en)
Norwegian (no)
Other versions
NO20014893D0 (no
Inventor
Wing K Cheung
Jaya Natarajan
Marilyn Sanders
Els Vercamen
Basant Sharma
Selima Begun
Original Assignee
Ortho Mcneil Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Mcneil Pharm Inc filed Critical Ortho Mcneil Pharm Inc
Publication of NO20014893D0 publication Critical patent/NO20014893D0/no
Publication of NO20014893L publication Critical patent/NO20014893L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • A61K38/1816Erythropoietin [EPO]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20014893A 1999-04-09 2001-10-08 Farmasoytiske sammensetninger av erythropoietin NO20014893L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12859699P 1999-04-09 1999-04-09
PCT/US2000/009414 WO2000061169A1 (en) 1999-04-09 2000-04-07 Pharmaceutical compositions of erythropoietin

Publications (2)

Publication Number Publication Date
NO20014893D0 NO20014893D0 (no) 2001-10-08
NO20014893L true NO20014893L (no) 2001-11-15

Family

ID=22436082

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20014893A NO20014893L (no) 1999-04-09 2001-10-08 Farmasoytiske sammensetninger av erythropoietin

Country Status (27)

Country Link
US (2) US6696056B1 (ko)
EP (1) EP1181036B1 (ko)
JP (1) JP2002541208A (ko)
KR (1) KR100740794B1 (ko)
CN (1) CN1165339C (ko)
AR (1) AR029623A1 (ko)
AT (1) ATE401908T1 (ko)
AU (1) AU775041B2 (ko)
BG (1) BG106046A (ko)
BR (1) BR0010665A (ko)
CA (1) CA2369444C (ko)
CY (1) CY1108418T1 (ko)
DE (1) DE60039598D1 (ko)
DK (1) DK1181036T3 (ko)
ES (1) ES2308978T3 (ko)
HK (1) HK1041445B (ko)
HU (1) HUP0201068A3 (ko)
IL (1) IL145816A0 (ko)
MX (1) MXPA01010208A (ko)
NO (1) NO20014893L (ko)
NZ (1) NZ515380A (ko)
PL (1) PL203797B1 (ko)
PT (1) PT1181036E (ko)
RU (1) RU2225221C2 (ko)
TR (1) TR200103788T2 (ko)
WO (1) WO2000061169A1 (ko)
ZA (1) ZA200109236B (ko)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7304150B1 (en) 1998-10-23 2007-12-04 Amgen Inc. Methods and compositions for the prevention and treatment of anemia
BR0010665A (pt) * 1999-04-09 2004-03-09 Ortho Mcneil Pharm Inc ComposiçÈes farmacêuticas de eritropoietina
US7371787B2 (en) * 2000-04-14 2008-05-13 Viance, Llc Methods of incorporating treatment agents into wood based composite products
JP3967594B2 (ja) * 2000-05-15 2007-08-29 エフ.ホフマン−ラ ロシュ アーゲー 新しい薬剤組成物
US6818613B2 (en) * 2001-11-07 2004-11-16 Ortho-Mcneil Pharmaceutical, Inc. Aqueous sustained-release formulations of proteins
BRPI0411114B8 (pt) * 2003-06-10 2021-05-25 Lg Chemical Ltd solução aquosa estável de eritropoetina humana, não contendo albumina de soro
DE10333317A1 (de) * 2003-07-22 2005-02-17 Biotecon Therapeutics Gmbh Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA)
KR20060095974A (ko) * 2003-09-23 2006-09-05 알콘, 인코퍼레이티드 트리암시놀론 아세토나이드 및 아네코르타브 아세테이트주사용 제제
US7141544B2 (en) * 2003-10-10 2006-11-28 Baxter International, Inc. Stabilization of pharmaceutical protein formulations with small peptides
DE202004020676U1 (de) 2004-03-10 2005-11-10 Bioceuticals Arzneimittel Ag Erythropoietin-Flüssigformulierung
US7588745B2 (en) * 2004-04-13 2009-09-15 Si Options, Llc Silicon-containing products
US20050255112A1 (en) * 2004-05-17 2005-11-17 Lee Jong Y Compositions and methods for preventing erythropoietin-associated hypertension
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
EP1789074A4 (en) * 2004-08-09 2009-08-12 Alios Biopharma Inc PROTEASE-RESISTANT HYPERGLYCOSYL SYNTHETIC POLYPEPTIDE VARIANTS, ORAL FORMULATIONS AND METHODS OF USING THE SAME
EP1909831A4 (en) 2005-06-14 2013-02-20 Amgen Inc PREPARATIONS OF SPONTANEOUS TAMPING PROTEINS
EP1916997B1 (en) 2005-08-05 2018-04-18 Amgen Inc. Stable aqueous protein pharmaceutical formulations and their preparation
CN101015684B (zh) * 2006-02-10 2011-08-24 华北制药集团新药研究开发有限责任公司 一种重组人红细胞生成素溶液制剂
US20080050749A1 (en) * 2006-08-17 2008-02-28 Ildiko Amann-Zalan Use of bnp-type peptides for the stratification of therapy with erythropoietic stimulating agents
WO2009064838A1 (en) 2007-11-15 2009-05-22 Amgen, Inc. Aqueous formulation of erythropoiesis stimulating protein stablised by antioxidants for parenteral administration
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
KR100956431B1 (ko) 2007-12-07 2010-05-06 주식회사 제이에스마루 혈장크린접착제 및 이의 제조방법
PE20110832A1 (es) 2008-09-26 2011-11-24 Ambrx Inc Polipeptidos de eritropoyetina felina modificados
KR102362829B1 (ko) 2012-09-07 2022-02-15 코히러스 바이오사이언시즈, 인코포레이티드 아달리무맙의 안정한 수성 제형
US11229702B1 (en) 2015-10-28 2022-01-25 Coherus Biosciences, Inc. High concentration formulations of adalimumab
WO2017184880A1 (en) 2016-04-20 2017-10-26 Coherus Biosciences, Inc. A method of filling a container with no headspace
US20180110856A1 (en) 2016-10-21 2018-04-26 Amgen Inc. Pharmaceutical Formulations and Methods of Making the Same
WO2018226747A1 (en) * 2017-06-06 2018-12-13 Kindred Biosciences, Inc. Erythropoietin and analogs for veterinary use
CN111150837B (zh) * 2020-02-11 2022-07-12 中国人民解放军陆军军医大学 Epo在抗金黄色葡萄球菌感染药物中的应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6191131A (ja) * 1984-10-09 1986-05-09 Chugai Pharmaceut Co Ltd 医薬品の吸着防止方法および組成物
JPS6197229A (ja) * 1984-10-18 1986-05-15 Chugai Pharmaceut Co Ltd 安定なエリトロポエチン製剤
DK173067B1 (da) * 1986-06-27 1999-12-13 Univ Washington Humant erythropoietin-gen, fremgangsmåde til ekspression deraf i transficerede cellelinier, de transficerede cellelinier sa
DE3729863A1 (de) 1987-09-05 1989-03-16 Boehringer Mannheim Gmbh Stabilisierte erythropoietin-lyophilisate
GB8822857D0 (en) 1988-09-29 1988-11-02 Patralan Ltd Pharmaceutical formulations
GB9001987D0 (en) * 1990-01-29 1990-03-28 Janssen Pharmaceutica Nv Improved cyclodextrin based erythropietin formulation
US5543575A (en) * 1990-06-20 1996-08-06 Pioneer-Hi-Bred International, Inc. Inbred corn line PHK46
DE4126983A1 (de) * 1991-08-15 1993-02-18 Boehringer Mannheim Gmbh Verfahren zur herstellung von humanprotein-enthaltenden, konservierten arzneimitteln fuer infusions- oder injektionszwecke
DE4126984A1 (de) * 1991-08-15 1993-02-18 Boehringer Mannheim Gmbh Verfahren zur herstellung von humanprotein-enthaltenden, gut vertraeglichen arzneimitteln fuer infusions- oder injektionszwecke
US5661125A (en) * 1992-08-06 1997-08-26 Amgen, Inc. Stable and preserved erythropoietin compositions
US5766582A (en) 1994-10-11 1998-06-16 Schering Corporation Stable, aqueous alfa interferon solution formulations
DE19539574A1 (de) * 1995-10-25 1997-04-30 Boehringer Mannheim Gmbh Zubereitungen und Verfahren zur Stabilisierung biologischer Materialien mittels Trocknungsverfahren ohne Einfrieren
TWI240627B (en) * 1996-04-26 2005-10-01 Chugai Pharmaceutical Co Ltd Erythropoietin solution preparation
TW586933B (en) 1996-06-20 2004-05-11 Chugai Pharmaceutical Co Ltd Compositions for treating liver-complaints using EPO
BR0010665A (pt) * 1999-04-09 2004-03-09 Ortho Mcneil Pharm Inc ComposiçÈes farmacêuticas de eritropoietina

Also Published As

Publication number Publication date
NO20014893D0 (no) 2001-10-08
CY1108418T1 (el) 2014-04-09
HUP0201068A3 (en) 2002-10-28
ZA200109236B (en) 2003-12-08
BG106046A (en) 2002-05-31
BR0010665A (pt) 2004-03-09
RU2225221C2 (ru) 2004-03-10
CA2369444C (en) 2009-08-18
ES2308978T3 (es) 2008-12-16
EP1181036A1 (en) 2002-02-27
CA2369444A1 (en) 2000-10-19
US20040248797A1 (en) 2004-12-09
CN1165339C (zh) 2004-09-08
DE60039598D1 (de) 2008-09-04
EP1181036B1 (en) 2008-07-23
HK1041445B (zh) 2009-07-03
AR029623A1 (es) 2003-07-10
MXPA01010208A (es) 2003-07-21
US6696056B1 (en) 2004-02-24
HK1041445A1 (en) 2002-07-12
AU775041B2 (en) 2004-07-15
NZ515380A (en) 2003-10-31
EP1181036A4 (en) 2004-04-21
HUP0201068A2 (en) 2002-08-28
CN1354669A (zh) 2002-06-19
PT1181036E (pt) 2008-10-03
KR20020016770A (ko) 2002-03-06
PL351837A1 (en) 2003-06-16
ATE401908T1 (de) 2008-08-15
JP2002541208A (ja) 2002-12-03
IL145816A0 (en) 2002-07-25
AU4218600A (en) 2000-11-14
TR200103788T2 (tr) 2002-05-21
WO2000061169A1 (en) 2000-10-19
DK1181036T3 (da) 2008-11-24
PL203797B1 (pl) 2009-11-30
KR100740794B1 (ko) 2007-07-20

Similar Documents

Publication Publication Date Title
NO20014893D0 (no) Farmasöytiske sammensetninger av erythropoietin
PT1242087E (pt) Composicoes farmaceuticas
NO20015175L (no) Farmasöytisk sammensetning
IS5046A (is) Lyfjasamsetningar
PT1066027E (pt) Composicao farmaceutica de topiramato
DE60033021D1 (de) Strukturierte kosmetische zusammensetzungen
FI991485A0 (fi) Uusi farmaseuttinen koostumus
AR028204A1 (es) Composiciones farmaceuticas electrohiladas
FR2775596B1 (fr) Nouvelles compositions pharmaceutiques
ITMI991754A0 (it) Composizioni cosmetiche
ATE258418T1 (de) Shampoozusammensetzungen
EE05020B1 (et) Glburiidi ravimkoostis
PT1239832E (pt) Composicoes farmaceuticas
DE60037014D1 (de) Kosmetische zusammensetzungen enthaltend polysaccharid-sterol-derivate
NO20016151D0 (no) Fremstilling av substituerte piperidin-4-oner
PT1227817E (pt) Composicao farmaceutica aquosa contendo ciclesonida
LU90483B1 (fr) Compositions nouvelles de m-thanesulfonate de parox-tine
FR2779145B1 (fr) Nouvelles compositions pharmaceutiques
EE200000459A (et) Farmatseutilised kompositsioonid
NO20042074L (no) Makrolider inneholdende farmasoytiske sammensetninger
FI981567A0 (fi) Farmaseuttiset koostumukset
SE9800052D0 (sv) Pharmaceutical compositions
SE9800330D0 (sv) Pharmaceutical compositions
ITMI992202A0 (it) Composizioni farmaceutiche contenenti farmaci antiinfiammatori
SE9902239D0 (sv) Kornisch bestående av flera delar

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application